RxDoctor Payments Data

Margaret McPherson, MD

Family Medicine · Bryn Mawr, PANPI 1316074461

Payments from drug & device makers

$5,126in general payments, 2019–2025

Across 259 payments — averaging $19.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$868
  • Novo Nordisk$757
  • Pfizer$545
  • GSK$401
  • Lilly USA, LLC$314
  • Bayer$298
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$5,117100%
  • Education$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,126 in reported general payments places this provider in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$173,246
Medicare patients
505
Services billed
2,345

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide47$82,754
EliquisApixaban82$56,788
JardianceEmpagliflozin46$51,673
XareltoRivaroxaban46$44,212
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$36,349
FarxigaDapagliflozin Propanediol28$32,224
MyrbetriqMirabegron32$31,176
KerendiaFinerenone23$29,306
RybelsusSemaglutide19$18,461
Breo ElliptaFluticasone/Vilanterol32$12,471
LinzessLinaclotide13$9,787
Atorvastatin Calcium739$9,247
Rosuvastatin Calcium343$6,606
Losartan Potassium517$6,130
Combivent RespimatIpratropium/Albuterol Sulfate12$5,646

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$757$101,21466 claims
PfizerEliquis, Paxlovid$545$59,647126 claims
Boehringer IngelheimJardiance, Combivent Respimat$235$57,31958 claims
GSKTrelegy Ellipta, Breo Ellipta$401$48,82174 claims
Johnson & JohnsonXarelto$26$44,21246 claims
AstraZenecaFarxiga$138$32,22428 claims
Astellas Pharma US IncMyrbetriq$236$31,17632 claims
BayerKerendia$298$29,30623 claims
AbbVieLinzess, Synthroid$868$12,83770 claims
Almatica Pharma LLCSertraline Hcl$42$1,432108 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Bryn Mawr

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →